Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis.
Nova Scotia has become the sixth Canadian jurisdiction and fifth province to implement a biosimilar switching policy in its public health program, a move which is expected to save the local government an estimated CAD13m ($10.2m) annually.
The Nova Scotia announcement follows the implementation of similar policies in British Columbia, Alberta, New Brunswick and Quebec. A fifth...
Generics Bulletin reviews global regulatory developments across the world.
A new life sciences strategy unveiled by the UK government has won plaudits from the off-patent industry for its inclusion of measures specifically geared towards generics and biosimilars – especially a £1bn savings target linked to biosimilar uptake.
Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.
Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.
